Vivos Therapeutics, Inc.
VVOS
$0.53
-$0.05-8.04%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 5.14M | 3.82M | 6.78M | 3.82M | 3.02M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.14M | 3.82M | 6.78M | 3.82M | 3.02M |
| Cost of Revenue | 2.08M | 836.00K | 2.85M | 1.71M | 1.51M |
| Gross Profit | 3.06M | 2.99M | 3.94M | 2.11M | 1.51M |
| SG&A Expenses | 9.22M | 8.93M | 8.29M | 6.67M | 5.25M |
| Depreciation & Amortization | 454.00K | 442.00K | 384.00K | 306.00K | 177.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.76M | 10.21M | 11.52M | 8.69M | 6.93M |
| Operating Income | -6.62M | -6.38M | -4.73M | -4.87M | -3.92M |
| Income Before Tax | -7.75M | -6.95M | -5.40M | -5.01M | -3.86M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -7.75M | -6.95M | -5.40M | -5.01M | -3.86M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 69.00K | 60.00K | -- | -- | -- |
| Net Income | -7.68M | -6.89M | -5.40M | -5.01M | -3.86M |
| EBIT | -6.62M | -6.38M | -4.73M | -4.87M | -3.92M |
| EBITDA | -6.16M | -5.94M | -4.35M | -4.56M | -3.74M |
| EPS Basic | -0.52 | -0.55 | -0.49 | -0.55 | -0.45 |
| Normalized Basic EPS | -0.33 | -0.35 | -0.31 | -0.34 | -0.28 |
| EPS Diluted | -0.52 | -0.55 | -0.49 | -0.55 | -0.45 |
| Normalized Diluted EPS | -0.33 | -0.35 | -0.31 | -0.34 | -0.28 |
| Average Basic Shares Outstanding | 14.63M | 12.42M | 10.96M | 9.09M | 8.60M |
| Average Diluted Shares Outstanding | 14.63M | 12.42M | 10.96M | 9.09M | 8.60M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |